About
Atox Bio is a late-stage biotechnology company that develops novel immunomodulators for critically ill patients. The companys lead product, Reltecimod, is initially being developed to treat necrotizing soft-tissue infection (NSTI), a rare, life-threatening infection for which no therapy currently exists. Atox Bio recently completed enrollment of the Reltecimod clinical composite endpoint study in necrotizing soft tissue infections study (ACCUTE), a phase 3 clinical trial evaluating the efficacy of Reltecimod in patients with NSTI. Results of the study are expected to be presented at a medical meeting in the first half of 2020. The companys previous phase 2 study of Reltecimod in NSTI demonstrated that patients treated with Reltecimod had a meaningful improvement across multiple endpoints. Reltecimod was granted fast track and orphan drug designations for NSTI by the FDA and orphan medicinal product designation for NSTI by the European Commission. Development of Reltecimod is supported by a contract from the Biomedical Advanced Research and Development Authority (BARDA).
Funding history · 4 rounds · $64.8M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is Atox Bio's primary focus and lead product?
- Atox Bio is a late-stage biotechnology company developing novel immunomodulators for critically ill patients. Its lead product, Reltecimod, is being developed to treat necrotizing soft-tissue infection (NSTI).
- What was the outcome of Atox Bio's Phase 3 ACCUTE trial for Reltecimod?
- In July 2020, Atox Bio announced a positive effect of Reltecimod on the resolution of organ dysfunction in its Phase 3 ACCUTE trial for patients with Necrotizing Soft Tissue Infection.
- When did Atox Bio receive FDA acceptance to file the NDA for Reltecimod?
- In December 2020, Atox Bio announced FDA acceptance to file the New Drug Application (NDA) for Reltecimod to treat suspected organ dysfunction or failure in patients with necrotizing soft tissue infection.
- What was the status of Atox Bio as of May 2022?
- According to startupim data, Atox Bio became inactive in May 2022, ceasing operations after the FDA required an additional trial for its product.
- Which organizations granted special designations to Reltecimod for NSTI?
- Reltecimod was granted fast track and orphan drug designations for NSTI by the FDA, and orphan medicinal product designation for NSTI by the European Commission.
- What was the total amount raised by Atox Bio through funding rounds?
- Atox Bio raised a total of $64.85 million through its funding rounds. For a full financing history, users can refer to startupim.
- When did Atox Bio complete its Series F funding round and who was a lead investor?
- Atox Bio completed its Series F funding round in December 2017, raising $30 million. Arix Bioscience was a lead investor in this round.
- Which government agency supported the development of Reltecimod?
- The development of Reltecimod was supported by a contract from the Biomedical Advanced Research and Development Authority (BARDA), which exercised an option period in June 2019 to continue support.